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Abstract
Several recent studies have reported that gold nanoparticles (AuNPs) attenuate
hyperglycemia in diabetic animal models without any observed side effects.
The present study was intended to provide insight into the effects of 50-nm
AuNPs on diabetic kidney disease. Adult male rats were divided into three
groups (n = 7/group): control (non-diabetic, ND), diabetic (D), and diabetic
treated intraperitoneally with 50-nm AuNPs (AuNPs + D; 2.5 mg/kg/day) for
7 weeks. Diabetes was induced by a single-dose injection of 55 mg/kg
streptozotocin. The result showed that AuNP treatment prevented diabetes-
associated increases in the blood glucose level. Reduction in 24-h urinary
albumin excretion rate, glomerular basement membrane thickness, foot process
width, and renal oxidative stress markers was also demonstrated in the AuNP-
treated group. In addition, the results showed downregulation effect of AuNPs
in renal mRNA or protein expression of transforming growth factor β1 (TGF-
β ), fibronectin, collagen IV, tumor necrosis factor-α (TNF-α), and vascular
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endothelial growth factor-A (VEGF-A). Moreover, the protein expression of
nephrin and podocin, podocyte markers, in glomeruli was increased in the
AuNPs + D group compared with the D group. These results provide evidence
that 50-nm AuNPs can ameliorate renal damage in experimental models of
diabetic nephropathy through improving the renal function and downregulating
extracellular matrix protein accumulation, along with inhibiting renal
oxidative stress and amelioration of podocyte injury.
AQ2
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Introduction
Diabetic nephropathy (DN) is the major cause of end-stage renal failure and
mortality in diabetic patients all over the world [1]. In DN, the first detected
histological alteration usually appears on glomeruli as a thickening of the
glomerular basement membrane (GBM) and tubular basement membrane (TBM)
[2]. Both GBM thickening and glomerular hyperfiltration lead to the progression
of microalbuminuria, while the leading cause for renal insufficiency in DN is the
mesangium expansion, which develops at a later stage [3]. The expanded
mesangium cells restrict and distort glomerular capillaries leading to the
collapsing of glomerular capillaries and in turn reducing the filtration surface and
decrease creatinine clearance [2, 4].
Mesangial expansion and GBM thickening occur as a result of increased
expression and accumulation of the extracellular matrix (ECM) proteins such as
collagen, fibronectin, and laminin in the mesangium and renal tubulointerstitium
of the glomerulus and basement membranes [5]. This subsequently resulted from
their increased production, decreased degradation, or both which eventually
resulting in renal fibrosis and DN [2, 4, 5, 6]. Chronic hyperglycemia is the
major initiator of these changes through increased oxidative stress,
overproduction and action of advanced glycation end products (AGCE), and
activation of several growth factors, such as transforming growth factor-β1
(TGF-β ) and vascular endothelial growth factor (VEGF-A) [7].1
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Podocytes are highly specialized cells that act as size and charge barriers to
protein and maintain the integrity of the glomerular filtration barrier [8]. One of
the significant events in the pathogenesis of DN is the progressive podocyte
injury, which expresses the recession of the podocyte foot processes that lead to
defacement, loss of slit diaphragm proteins, detachment, and finally cell
apoptosis [9]. Different studies have shown that the development of albuminuria
and the acceleration of glomerular structural abnormalities in DN are associated
with podocyte injury and loss [8].
Despite the available modern therapies that can delay the onset of DN (glucose
and blood pressure control drugs), numerous patients continue to show
progressive renal damage. Thus, it is extremely necessary to identify novel
therapeutic strategies that could specifically target the progression of DN [10].
Recently, nanoparticles (NPs) have been widely used in biomedical applications
because they can pass through biological barriers and their ability to enhance the
bioavailability of therapeutic agents [11, 12]. Several studies have revealed that
gold nanoparticles (AuNPs) exhibited anti-hyperglycemic, anti-inflammatory,
and anti-oxidative activities in streptozotocin (STZ)-induced diabetic animal
model [13, 14]. Hyperglycemia and oxidative stress are important factors in the
development of diabetic microvascular complications including DN [15, 16].
Recent studies have demonstrated that pomegranate peel extract-stabilized 20-nm
AuNPs and 13-nm naked AuNPs reduced STZ-induced renal fibrosis,
inflammation, and oxidative stress [17, 18]. However, the maximized kidney
targeting at the cellular (mesangium), tissue, and organ levels will be achieved
via the usage of 50-nm AuNPs [19]. To the best of our knowledge, the effects of
50-nm AuNPs on the albuminuria, podocyte injury, oxidative stress,
inflammation, and angiogenesis have not yet been studied in DN. The goals of
the current study were to demonstrate the effects of 50-nm AuNPs in the STZ-
induced diabetic rats and to explore their protective effects against diabetic
albuminuria and podocyte injury.
Materials and methods
Materials
Sodium citrate trihydrate, HAuCl , RNAlater solution, and Periodic Acid Schiff
staining kit were all provided from Sigma-Aldrich, (St. Louis, USA).
Streptozotocin and antibodies against TGF-β  ( Cat. No. sc -146) were both
purchased from Santa Cruz biotechnology (Santa Cruz, USA). Albumin Rat
ELISA kit, HRP/DAB IHC Detection Kit-Micropolymer, and the primary
antibodies against Collagen IV (Cat. No. ab6586), Fibronectin (Cat. No.ab2413),
nephrin (Cat. No.ab1830990), podocin (Cat.No.ab50339) were all provided from
4
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Abcam (Cambridge, UK). The superoxide dismutase assay kit was purchased
from Cayman Chemical, (Ann Arbor, USA). Catalase assay kit was provided
from Abbexa (Cambridge, UK). The Total RNA extraction kit was from iNtRON
Biotechnology, Inc. (Seongnam, Korea). cDNA reverse transcription kit and
SYBR green PCR master mix were purchased from Takara (Beijing, China). All
primers were synthesized by Integrated DNA Technologies, INC. (Coralville, IA,
USA). All other chemicals, buffers, and solvents used were of pure analytical
grade.
Synthesizing and characterization of AuNPs
The preparation and characterization of AuNPs were mentioned in our previous
report [20]. In brief, 300 μl of an aqueous solution of 1% (w/v) HAuCl  was
added to 30 ml of ultra-pure H O and brought to boil on magnetic hotplate (BT
lab system, UK) while gently stirring at 150 rpm. Once the solution reaches
boiling, 900 μl of freshly prepared aqueous of 1% (w/v) sodium citrate trihydrate
was added to the reaction mixture. The reaction was allowed to proceed for
10 min where the AuNP formation was completed as indicated by the color
transformation to ruby-red from yellow. Size and morphology of the resulted
AuNPs were characterized using a scanning electron microscope (Quanta FEG
SEM, Thermo Fisher Scientific, UK), dynamic light scattering (DynaPro Titan
Wyatt Technology Corporation) equipped with a laser wavelength of λ = 830 nm,
scattering angle of 2° equipped with Dynamics software version 6.9.2.11, and
zeta potential instruments were recorded on (Malvern Instruments Zetasizer-
Nano ZS) in which 0.2 mg was suspended in 1 ml of 0.1 M sodium phosphate
buffer pH 7.0. Zeta cells were pre-equilibrated at 21 °C with the buffer, and data
were presented from 3 independent synthesis.
Induction of diabetes and experimental protocols
All animal experimental procedures were carried out in accordance with the
National Institutes of Health guidelines for the care and use of laboratory animals
and approved by the committee of animal ethics at Yarmouk University )
(permission number: YU-20/12/2017)(. Adult male Wistar rats weighting 250 to
300 g were maintained under specific pathogen-free conditions at the animal
house unit at Yarmouk University. After 1 week of adaptation, diabetes was
induced by a single intraperitoneal injection of streptozotocin (STZ) (55 mg/kg;
following overnight fasting). Three days after STZ injection, rats with a blood
glucose level over 250 mg/dl were considered diabetic. Rats were divided into
three groups (n = 7/group): control (non-diabetic, ND), diabetic (D), and diabetic
treated intraperitoneally with 50 nm AuNPs (AuNPs + D; 2.5 mg/kg) daily for
7 weeks.
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The size, dose, and the route of administration of AuNPs used in the present
study were selected based on the previous study that reported that intraperitoneal
administration of spherical, 50-nm AuNPs showed anti-hyperglycemia and anti-
oxidative effect in STZ-induced diabetic mice without toxic effect over the vital
organs [13].
Urine, blood, and tissue collection
At the end of 7 weeks of treatment, the rats were placed in metabolic cages 1 day
before sacrifice, and urine was collected for 24 h for the analysis of urine
albumin concentration and the urine output. Then, the animals were weighed and
lightly anesthetized with ethyl ether, and blood samples were collected (via
cardiac puncture). The animals were sacrificed using an overdose of ethyl ether.
The right kidney was removed and then transferred into RNAlater solution for
the real-time PCR analysis. The left kidney was fixed with 4% paraformaldehyde
for morphological and immunohistochemical analysis.
Measurements of blood glucose, 24-h urinary albumin
excretion rate, and renal oxidative stress markers
The blood glucose level was determined by glucometer (Accu-Chek Performa,
Roche Diagnostics). Urine samples were centrifuged at 4 °C and 2000 rpm for
10 min. The urinary albumin in the supernatant was measured using Albumin Rat
ELISA kit according to the manufacturer’s protocols.
Kidney tissues were homogenized in protein extraction buffer containing PBS
and protease inhibitor. Commercially available kits were used according to the
manufacturer protocols to identify the activities of superoxide dismutase and
catalase. The renal malondialdehyde (MDA) level, a marker of lipid
peroxidation, was assessed by a method described previously [21]. In brief, renal
tissue homogenate (0.2 mg protein/ml) was combined with 2.0 ml of
thiobarbituric acid (TBA), trichloroacetic acid (TCA), and TCA-TBA-HCI and
was mixed thoroughly. Then, the solution was heated for 15 min in a boiling
water bath, and after cooling, the flocculent precipitate was removed by
centrifugation at 1000g for 10 min. The absorbance of the sample was
determined at 535 nm against a blank that contains all the reagents minus the
lipid.
Morphology studies
After the fixation in 4% paraformaldehyde, the tissues were dehydrated in
ascending series of alcohol, cleared in xylene, embedded in paraffin, sectioned at
4 μm, and stained with hematoxylin and eosin (H&E) and periodic acid-Schiff.
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For electron microscopy study, renal cortical tissues were cut into 1-mm  cubes,
fixed in 2.5% glutaraldehyde dissolved in 0.1 M sodium cacodylate buffer
(v/v%) (pH 7.4) for 1 h, and then washed in the same buffer. The tissue
fragments were post-fixed in sodium cacodylate-buffered 1% OsO  (v/v%) for
2 h, dehydrated, and embedded in Spurr’s resin. Ultra-thin sections were cut
using ultra-microtome (Reichert-Jung, Austria), contrasted with 4% uranyl
acetate for 45 min, and subsequently incubated with lead citrate for 4 min at
room temperature. Sections were examined under a Hitachi electron microscope
(HT7700-Tokyo). The GBM thickness was measured and calculated as
previously detailed [22]. The degree of podocyte detachment was calculated as
the mean of foot process width (FPW). From each photograph, the arithmetic
mean of the FPW was calculated according to the equation below [23]:
where Ʃ GBM length is the total GBM length measured in each photo and Ʃ foot
process is the total number of foot processes counted in that photo. To correct for
supposed random difference in the angle of section relative to the long axis of the
podocyte, the correction factor of π ̸4 was used. GBM length was calculated by
computerized measurement using the ImageJ software. Podocyte foot processes
number was computed by hand [23].
Immunohistochemistry
Immunohistochemical staining was performed with mouse and rabbit-specific
HRP/DAB IHC Detection Kit-Micropolymer, according to the manufacturer’s
protocol using specific primary antibodies against TGF-β , ECM proteins, and
podocyte markers as follows: collagen IV (1:100), fibronectin (1:50), nephrin
(1:100), podocin (1:50), and TGF-β  (1:100). Negative controls were run by
replacing the primary antibody with PBS. Sections were examined under an
Optika microscope and evaluated using Fiji ImageJ software.
Real-time PCR
Total RNA was extracted from RNAlater-preserved kidney tissues using Total
RNA extraction kit according to the manufacturer’s protocols. RNA quantity was
determined using QuantiFluor RNA System (Promega, Madison, USA) and
Quantus Fluorometer (Promega, Madison, USA). A cDNA reverse transcription
kit was used to prepare the cDNA template, according to the manufacturer’s
instructions. Quantitative real-time PCR was conducted using LineGene 9600
Real-Time PCR system (Bioer Technology Co., Binjiang, China), with the SYBR
green PCR master mix, at 95 °C for 2 min and 45 cycles of 95 °C for 30 s, and
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60 °C for 30 s. GAPDH was used as a non-regulated reference gene. PCR
primers of TGF-β , VEGF-A, collagen IV, fibronectin, and TNF-α primers were
designed using Primer3 ( http://www.ncbi.nlm.nih.gov/tools/primer-blast/ )
software and synthesized by IDT (Table 1). To ensure the specificity of the
primers, a gel was run, in which a single band of expected size was obtained. The
fold changes in the mRNA expression were determined using the 2  method
[24].
Table 1
Sequences of primers used for quantitative real-time PCR
Gene Forward (5–3) Reverse (5–3)
GAPDH ATG GTG AAG GTC GGT GTG GAA CTT GCC GTG GGT AGA
TGF-β GTG GAG CAA CAC GTA GAAC TCC TTG GTT CAG CCA CT
VEGF-A CGA ACA GAG AGA GGG ACAGG
GTC TGT CTG TCT GTC CGT
CA
Fibronectin TGA CCG ACG CTA CAG AAACT
TTG AGC GTG TAC AGG TGG
AT
TNF-α TTC GGA ACT CAC TGG ATCCC
GGA ACA GTC TGG GAA GCT
CT
Collagen
IV
TTG GCT TTC CTG GTA GTC
GT
CAA CCT TTC CTG CTT CAC
CC
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TGF-β , transforming growth
factor-β1; VEGF-A, vascular endothelial growth factor-A; TNF-α, tumor necrosis
factor-α
Statistical analysis
All data are expressed as the mean ± SEM; the minimum number of replicates
used in the analysis was 6. Differences between groups were calculated by one-
way analysis of variance (ANOVA) using SPSS software (SPSS Inc., Chicago,
IL). The significant value of difference was considered when the P value < 0.05.
Results
Characterization of AuNPs
Characterization of the generated particles revealed that the generated AuNPs
mainly consist of spherical particles with an average hydrodynamic diameter of
51.8 ± 0.7 nm and with a polydispersity index of 0.26%. Furthermore, the surface
zeta potential related to the surface charge was − 40.0 ± 0.2 [20].
1
−ΔΔCT
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Effect of AuNPs on metabolic and biochemical parameters
After 7 weeks of STZ administration, diabetic animals showed significant
increases in the blood glucose level, kidney weight/body weight ratio, and 24-h
urinary albumin excretion rate, indicating that we successfully established an
experimental animal model of type 1 diabetes possessing DN (P < 0.05; Table 2).
Treatment with AuNPs did not affect the kidney weight/body weight ratio in
diabetic rats significantly. However, the AuNP treatment significantly decreased
blood glucose level and 24-h urinary albumin excretion rate compared with the D
group (P < 0.05; Table 2).
Table 2
Effect of AuNPs on metabolic and biochemical parameters
Parameters ND
D AuNPs + D
Mean ± SEM Pvalue* Mean ± SEM
P
value
Blood glucose
(mg/dl) 113.1 ± 5.6 340.83 ± 42.11*
< 
0.0001 144.1 ± 25.48
< 
0.0001
Kidney
weight/body
weight ratio
0.60 ± 0.02 1.12 ± 0.02* < 0.0001 1.035 ± 0.085 0.1992
Urinary albumin
excretion rate
(mg/day)
0.14 ± 0.04 0.68 ± 0.06* < 0.0001 0.32 ± 0.07 0.0004
Data represent the mean ± SEM. *P value compared with the ND group. P value
compared with D. ND, non-diabetic; D, diabetic; AuNPs, gold nanoparticles
Renal histopathological and ultrastructural changes
The histological morphology showed organized intact glomeruli, Bowman’s
capsule, and tubular structure in the ND group (Fig. 1a). In contrast, the
histological examination of the renal tissue in the D group showed disorganized
architecture characterized by expansion in urinary space and closure of capillary
loops and tubular atrophy and increased vacuolization of renal tubular epithelial
cells. However, AuNP treatment ameliorates these abnormal histological findings
in the AuNPs + D group. Light microscopy sections of PAS staining showed
mesangial expansion and thick basement membranes in the D group compared
with the ND group) Fig. 1b). While in AuNPs + D group, GBM showed normal
thickness with decreased in mesangial matrix deposition.
Fig. 1
$
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a H&E-stained sections (magnification, × 400) show intact and organized structure
glomerulus in the ND group. Disorganized architecture of glomerulus in the D
group and normal glomeruli the AuNPs + D group. Asterisk indicates expansion in
urinary space. b PAS-stained sections (magnification, × 1000) show that the
percentage of the PAS-positive material, indicative of increased fibrosis, was
significantly increased in the D group compared with the ND group. Arrow head:
basement membrane thickening, arrow: mesangial expansion. AuNP treatment
inhibited the increase in the PAS-positive material in the AuNPs + D group
Several ultrastructural abnormalities were present in the electron microscopy
sections (Fig. 2) in the D group such as diffused thickening of the GBM, a
reduction in the podocyte number, and diffused foot process effacement, along
with a reduced podocyte per glomerulus ratio. Treatment of diabetic rats with
AuNPs ameliorated the above pathogenic findings.
Fig. 2
Glomerular ultrastructure in the different treated groups. a Representative electron
microscopy images of podocyte foot processes and the GBM (magnification: ND
and AuNPs + D × 6000, D × 8000). White arrow: foot process effacement. b
Glomeruli were evaluated to quantify the GBM thickness. *P < 0.05 compared
with the ND group. P < 0.0001 compared with D, number of podocyte. *P < 0.05
compared with the ND group. P < 0.0025 compared with D and FPW. *P < 0.05
compared with the ND group. P < 0.0001 compared with D. Data represent the
mean ± SEM. ND, non-diabetic; D, diabetic; AuNPs, gold nanoparticles; GBM,
glomerular basement membrane thickness; FPW, foot process width; P, podocyte
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Effect of AuNPs on renal oxidative stress markers
Diabetic animals showed significant decreases in the renal tissue SOD and
catalase activities and increase in the MDA level compared with the ND group
(P < 0.05; Table 3). Notably, AuNP administration restored the renal SOD and
catalase activity and the MDA level to the normal values.
Table 3
Effect of AuNPs on renal oxidative stress markers
Parameters ND
D AuNPs + D
Mean ±
SEM P  value* Mean ± SEM
P  value
SOD (U/mg) 2.84 ± 0.14 2.07 ± 0.36 0.043 2.90 ± 0.20 0.046
Catalase (U/mg) 5.54 ± 0.89 1.67 ± 0.31 0.015 4.82 ± 1.29 0.035
MDA (μmol/mg) 0.12 ± 0.04 0.49 ± 0.17 0.014 0.17 ± 0.045 0.028
Data represent the mean ± SEM. *P value compared with the ND group. P value
compared with D. ND, non-diabetic; D, diabetic; AuNPs, gold nanoparticles; SOD,
superoxide dismutase; MDA, malondialdehyde
$
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Effect of AuNPs on the renal expression of fibrosis,
angiogenesis, and inflammation markers
The immunohistochemistry analysis demonstrated that diabetes was associated
with an increase in the intensity of immunostaining for collagen IV, fibronectin,
and TGF-β  (Fig. 3a, b), which are the major ECM proteins that lead to the
development of the mesangial matrix expansion in the status of DN [25].
Consistent with the immunohistochemical findings, the levels of mRNA
encoding for fibronectin and TGF-β  were significantly greater in the D than in
the ND group (Fig. 4a, b; P < 0.05). However, the collagen IV mRNA levels did
not differ significantly between D and AuNPs + D groups (Fig. 4c; P > 0.05).
The treatment of diabetic rats with AuNPs downregulates the expression of these
fibrosis markers, suggesting that AuNP treatment inhibits the progression of
renal fibrosis in the AuNPs + D group.
Fig. 3
Immunohistochemistry detects that AuNP treatment inhibits the collagen IV,
fibronectin, and TGF-β  expression in the diabetic kidney. a Immunohistochemical
stain of the kidney sections (magnification, × 400) shows that the immunostaining
(brown staining) in the glomeruli was much stronger in the D group compared with
the ND group. AuNP treatment inhibited the increase in the immunostaining in the
AuNPs + D group. b Immunohistochemistry optical density score. Data represent
the mean ± SEM. (COL-IV *P < 0.05 compared with the ND group, P < 0.0001
compared with D. Fibronectin *P < 0.05 compared with the ND group, P = 0.0074
compared with D. TGF-β  *P < 0.05 compared with the ND group, P < 0.0001
compared with D). ND, non-diabetic; D, diabetic; AuNPs, gold nanoparticles;
TGF-β , transforming growth factor-β
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Fig. 4
Effect of AuNP treatment on the mRNA expression in the normal and diabetic
kidney. a Fibronectin, *P < 0.05 compared with the ND group; P < 0.0001
compared with D. b TGF-β , *P < 0.05 compared with the ND group; P = 0.0008
compared with D. c Collagen IV, *P < 0.05 compared with the ND group; P = 0.15
compared with D. d VEGF-A, *P < 0.05 compared with the ND group; P = 0.0006
compared with D. e TNF-α; *P < 0.05 compared with the ND group; P = 0.0082
compared to D. Data represent the mean ± SEM. ND, non-diabetic; D, diabetic;
AuNPs, gold nanoparticles; TGF-β , transforming growth factor-β ; VEGF-A,
vascular endothelial growth factor-A; TNF-α, tumor necrosis factor-α
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Upregulation in the expression of VEGF-A, an angiogenic factor, and TNF-α, an
inflammatory marker is often observed in the DN. Figure 4 d and e show that the
mRNA expression levels of VEGF-A and TNF-α were significantly increased in
the D group compared with the ND group (P < 0.05). However, the treatment
with AuNPs downregulates the expression of VEGF-A and TNF-α in the AuNPs
+ D group.
Effects of AuNP treatment on the expression of podocyte
markers (nephrin and podocin)
The expression intensity and the distribution pattern of nephrin and podocin in
the glomeruli were assessed by immunohistochemical staining (Fig. 5a). In the D
group, the expression intensity of nephrin and podocin were significantly
decreased compared with the ND group (Fig. 5b, P < 0.05). However, AuNPs
fully improved the immunohistochemical staining intensity of both podocyte
markers in the AuNPs + D group.
Fig. 5
Immunohistochemistry detects that AuNP treatment restores the nephrin and
podocin expression in the diabetic kidney. a Immunohistochemical stain of the
kidney sections (magnification, × 400) shows that the immunostaining (brown
staining) in the glomeruli was much stronger in the ND group compared with the D
group. AuNP treatment inhibited the decrease in the nephrin and podocin
immunostaining in the AuNPs + D group. b Immunohistochemistry optical density
score. Data represent the mean ± SEM. (Nephrin; *P < 0.05 compared with the ND
group. P < 0.0001 compared with D. Podocin; *P < 0.05 compared with the ND$
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group. P = 0.0006 compared with D). ND, non-diabetic; D, diabetic; AuNPs, gold
nanoparticles
Discussion
Due to their unique physical and chemical properties, many pieces of research
have been conducted to elucidate their potential efficiency in the treatments of
many diseases. Accordingly, using AuNPs as a promising antidiabetic agent just
started to emerge [13, 26, 27, 28]. To explore the effect of AuNPs on the DN, an
experimental DN similar to DN in type 1 diabetic patient was established
successfully in this study that characterized by hyperglycemia and albuminuria
that were associated with the loss of podocytes, effacement of foot process, and
thickening of the GBM and glomerulosclerosis [2]. Our results revealed that 50-
nm AuNPs effectively ameliorated DN in a rat model of STZ-induced type 1
diabetes.
Podocytes play a major role in maintaining the integrity and permeability of the
glomerular filtration barrier [8]. In DN, a reduction in podocyte number, the
effacement of podocyte foot processes, and the loss of slit diaphragm proteins
such as nephrin and podocin result in a leakage of albumin and proteinuria [29].
The results of the present study showed that the levels of urinary albumin were
significantly increased in diabetic rats which were associated with the loss of
podocytes, widening and effacement of foot process, and decrease in the staining
intensity of nephrin and podocin. Our data indicated that AuNPs significantly
reduced albuminuria and the podocyte ultrastructural abnormalities and restored
$
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the staining intensity of nephrin and podocin, suggesting a protective effect for
AuNPs on the structure of podocytes in the diabetic conditions.
In addition, GBM and TBM thickening along with mesangial expansion seem to
be a critical determining factors for the progress of proteinuria and the advance
of kidney dysfunction in DN [30]. Both mesangial expansion and GBM and
TBM thickening are a consequence of ECM protein accumulation due to their
increased production, decreased degradation, or both [2]. Our results showed that
the GBM thickening was significantly lower in the AuNPs + D rats compared
with the D group. In addition, the upregulation of tissue collagen and fibronectin,
the major constituent of ECM proteins, in the diabetic kidney is effectively
reversed after the AuNP treatment. Many studies support a role for
hyperglycemia in the increased synthesis of many ECM proteins that accumulate
within the mesangium and GBM of diabetic kidneys resulting in changes in
permeability of the filtration barrier [31]. Improved glycemic control in patients
with diabetes is, therefore, a goal in the attempt to slow the rate of progression of
diabetic renal disease [32]. ECM accumulation in diabetes is induced by TGF-β ,
which enhances collagen, fibronectin, and laminin synthesis and inhibits proteins
that mediate the ECM protein degradation [33]. Studies have shown that high
glucose environment could increase TGF-β  expression in renal tubular epithelial
cells and activate ECM protein deposition in glomeruli [34]. Therefore, the TGF-
β  pathway is a therapeutic target for DN [35]. In this study, TGF-β  mRNA and
protein levels were increased in the D group and reduced in the AuNP-treated
rats, which is in turn reduce the accumulation of the ECM proteins, collagen IV,
and fibronectin. This may provide insight into the mechanism whereby AuNP
contributes to reduced mesangial matrix expansion in the diabetic condition.
Consistent with our results, AuNPs significantly decreased the expression of
fibronectin and TGF-β  and inhibit matrix deposition in pancreatic ductal
adenocarcinoma [36]. The exogenous administration of AuNPs is documented to
afford protection against liver fibrosis [37]. In addition, gold nanorods modulate
cell-mediated matrix remodeling and decrease the mRNA expression of type I
collagen in neonatal rat cardiac fibroblasts [38].
Oxidative stress, defined as an imbalance in the oxidant/antioxidant production,
has been considered to be one of the primary factors for the development of DN
[15, 16]. Excessive production of reactive oxygen species (ROS) in multiple cell
types including mesangial cells and podocytes activates various protein kinases,
cytokines, and transcription factors which eventually cause increased expression
of ECM proteins and progression to renal fibrosis [31, 39]. Thus, neutralizing the
ROS induced by hyperglycemia is effective in preventing experimentally induced
diabetes and its complications such as DN [40]. SOD and catalase are considered
the key antioxidant enzymes which detoxify ROS to water in the kidney [1]. In
1
1
1 1
1
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our study, AuNP treatment significantly reduced the renal oxidative stress by
increasing the activities of renal SOD and catalase and by reducing the tissue
MDA level. These results were in agreement with previous in vivo studies that
showed that AuNPs have anti-oxidative and anti-hyperglycemic activities in
diabetic animal models [13, 41].
Several studies have shown the crucial role of kidney inflammation in promoting
the development and progression of DN [42, 43, 44]. In particular, inflammatory
cytokines have emerged as being closely involved in the pathogenesis of DN
[45]. For instance, TNF-α has been reported as one of the major inflammatory
cytokines that is believed to play an important role in the pathogenesis of DN.
TNF-α has been reported to be responsible for the production of ROS, induction
of cell injury, and increases in endothelial permeability [44, 45]. In the present
study, AuNPs were found to be associated with the suppression of the
inflammation in the AuNPs + D group. Specifically, treatment with AuNPs
showed a significant reduction in the mRNA expression levels of TNF-α down to
the normal levels as compared with the D group, indicating the effect of AuNPs
on suppressing the inflammation through preventing TNF-α over expression.
This result is consistent with other studies which described AuNP as an anti-
inflammatory agent in different diseases including diabetes [14, 46, 47, 48].
Moreover, vascular endothelial growth factor (VEGF) is the most potent
angiogenic factor and its upregulation often is observed in many pathologic
conditions including DN [49]. Upregulated VEGF synthesis is accompanied by
the glomerular hypertrophy and urinary albumin excretion in the DN [10, 49,
50]. Several studies have indicated that VEGF mRNA, protein expression, and
activity are enhanced in kidneys with early DN [51, 52, 53, 54]. In the current
study, the level of VEGF-A was significantly increased in the kidney of diabetic
rats. However, AuNP treatment successfully reversed the increase in the
expression of the VEGF in the AuNPs + D group. Our findings underscored the
role of AuNPs as anti-angiogenic treatment, which is consistent with previous
findings [55]. Nevertheless, the mechanism of action of the AuNPs as anti-
angiogenic factor is not fully understood; however, previous report proposed that
the AuNPs inhibit the activity of heparin-binding growth factors (HB-GFs) such
as vascular endothelial growth factor 165 (VEGF165) and basic fibroblast
growth factor (bFGF) by the change in HB-GF conformation/configuration
(denaturation) by the AuNPs [55].
Finally, due to the variability of parameters such as the size and surface charge of
the particle, cell type, and dosing parameters, no straightforward deduction has
arisen from the available studies regarding AuNP toxicity. However, a great
advantage of AuNPs over other nanoparticles is that they show no cytotoxicity in
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human cells [56]. In the current study, daily administration of 50-nm AuNPs for
7 weeks was well tolerated by the animals (no significant changes in the feed
intake, mortality rate, and behavior). In addition, the analysis of hepatic function
showed no significant effects of 50-nm AuNP treatment on the serum aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) levels (data not
shown).
Conclusion
The results of this study demonstrated a potential curing efficiency of AuNPs on
DN. The study outcomes confirmed that STZ treatment clearly raised the blood
glucose level which enhanced oxidative stress and inflammation. The adverse
effects of these outcomes were evident in renal tissue indicated by the
accumulation of ECM proteins, GBM thickening, and podocyte injury which
eventually lead to albuminuria. In contrast, AuNPs were able to show promising
effects in preventing the adverse effects of hyperglycemia in renal tissue by
preventing the accumulation of ECM proteins and the amelioration of podocyte
injury through the downregulation of growth factors, inflammatory, and
angiogenesis markers. In summary, the current study proposed a potential use of
AuNPs for the treatment and prevention of diabetic nephropathy complications;
however, future functional studies are required to understand the exact molecular
mechanism of action at cellular and physiological levels.
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